十六烷基三甲基铵 | 6899-10-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 十六烷基三甲基铵
• 中文别名: 烷铵五氯酚
• 英文名称: hexadecyltrimethylammonium cation
• 英文别名: Cetrimonium；hexadecyl(trimethyl)azanium
• CAS: 6899-10-1
• 化学式: C₁₉H₄₂N
• 分子量: 284.549
• InChiKey: RLGQACBPNDBWTB-UHFFFAOYSA-N

物化性质

• 熔点：
  240 °C
• 溶解度：
  100000 mg/L

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  20
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

ADMET

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

安全信息

• 海关编码：
  2923900090

反应信息

• 作为反应物：
  描述：

  、 十六烷基三甲基铵 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Reactions of Gas-Phase Salts:  Substitutions and Eliminations in Complexes Containing a Dianion and a Tetraalklylammonium Cation

  摘要：

  [GRAPHICS]Electrospray ionization has been used to generate gas-phase complexes of a dianion (4 carboxy-4'-sulfodiphenylacetylene) with a series of tetraalkylammonium cations. The salt complexes are stable within a quadrupole ion trap but readily react during collision activated dissociation to give substitution and elimination products (alkylation or protonation of the carboxylate with the loss of a trialkylamine). Ab initio calculations at the MP2/6-31 +G(d,p)/MP2/6-31 +G(d) level are presented for the corresponding reactions of a model system, acetate + ethyltrimethylammonium.

  DOI：

  10.1021/ol990104i
• 作为产物：
  描述：

  在 Sodium tetraborate decahydrate 、 1-苯甲基-1,4-二氢烟酰胺 、 氧气 、 亚甲兰 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 十六烷基三甲基铵 、 β-环糊精
  参考文献：
  名称：

  离子表面活性剂和环糊精对1-苄基-1,4-二氢烟酰胺与亚甲蓝氢化物转移反应的影响

  摘要：

  在含有环糊精（β- 和 γ-CD）和表面活性剂（十二烷基硫酸钠 (SDS) 的培养基中研究了亚甲蓝 (MB + ) 和 1-苄基-1,4-二氢烟酰胺 (BNAH) 之间的氢化物转移反应的动力学） )、十二烷基三甲基溴化铵、十四烷基三甲基溴化铵和十六烷基三甲基溴化铵)。阳离子表面活性剂降低了高于 cmc 的表观一级速率常数 (k obsd )，而 SDS 增加了刚好高于 cmc 的 k obsd ，然后随着表面活性剂浓度的增加而降低 k obsd。由于反应物被胶束分离，阳离子表面活性剂的这种行为是典型的胶束效应。BNAH 与胶束相关，而 MB + 离子被胶束的阳离子界面排斥。BNAH 和 MB + 与相同 SDS 胶束的结合增强了反应，但是随着 [SDS] 的增加，胶束界面内的试剂稀释导致 k obsd 降低。在 β-CD-阳离子表面活性剂混合物中，根据模型解释结果，该模型考虑了 CD-BNAH、CD-MB

  DOI：

  10.1246/bcsj.80.1383
• 作为试剂：
  描述：

  calcium(II) nitrate 、 potassium hydrogenphosphate trihydrate 在 十六烷基三甲基铵 作用下， 反应 35.0h， 生成 hydroxyapatite
  参考文献：
  名称：

  Vincristine-loaded hydroxyapatite nanoparticles as a potential delivery system for bone cancer therapy

  摘要：

  Despite advances in the development of new therapeutic agents and diagnostic imaging techniques, the 5-year survival of osteosarcoma, the most common type of bone cancer, remains practically unaltered for the last three decades at around 60%. Nanoparticle-based carriers have emerged as new class of drug delivery systems that could potentially overcome conventional chemotherapy limitations, by promoting a better drug biodistribution profile by allowing a preferential accumulation of the drug in the desired tissue, while minimising non-targeted tissue toxicity, thus resulting in an improved overall therapeutic effectiveness. Hydroxyapatite nanoparticles (HANP) are known to be biocompatible and non-immunogenic and have shown to be preferentially accumulated in bone tissues being considered a promising carrier to bone tissues. Herein, we successfully synthesised mesoporous hydroxyapatite nanoparticles with mean size of 285.32 +/- 10.29 nm and superficial area of 103.5 m(2)/g, containing significant quantities of chemotherapeutic drug vincristine. A spectrophotometric method was developed and validated aiming to quantify the vincristine (VCR)-loaded in nanoparticles. Chorioallantoic membrane assay revealed relevant anti-angiogenic activity of system, leading to accentuated reduction in the number of blood vessels in fertilised eggs. Findings presented in this paper suggested that VCR-loaded HANP has a promising future as a nanocarrier for bone cancer treatment.

  DOI：

  10.1080/1061186x.2017.1401078

文献信息

• PROCESS FOR PRODUCING 1,1-DICHLORO-2,3,3,3-TETRAFLUOROPROPENE AND 2,3,3,3-TETRAFLUOROPROPENE
  申请人：SEKI Ryuji

  公开号：US20110319678A1

  公开（公告）日：2011-12-29

  To provide a process to produce 1,1-dichloro-2,3,3,3-tetrafluoropropene (CFO-1214ya) simply and economically without requiring purification of 1,1-dichloro-2,2,3,3,3-pentafluoropropane (HCFC-225ca) from the raw material component obtained as a mixture of isomers, i.e. dichloropentafluoropropane (HCFC-225) including HCFC-225ca and at the same time to produce simply and economically 2,3,3,3-tetrafluoropropene (HFO-1234yf) from 1-chloro-2,3,3,3-tetrafluoropropane (HCFC-244eb). A raw material composition comprising HCFC-244eb and HCFC-225 including HCFC-225ca is contacted with an alkali aqueous solution in the presence of a phase-transfer catalyst to produce CFO-1214ya from HCFC-225ca and at the same time to produce HFO-1234yf from HCFC-244eb.

  提供一种简单经济的方法来生产1,1-二氯-2,3,3,3-四氟丙烯（CFO-1214ya），无需从作为异构体混合物获得的原料组分中纯化1,1-二氯-2,2,3,3,3-五氟丙烷（HCFC-225ca），即二氯五氟丙烷（HCFC-225）包括HCFC-225ca，并同时简单经济地生产2,3,3,3-四氟丙烯（HFO-1234yf）从1-氯-2,3,3,3-四氟丙烷（HCFC-244eb）。 将包括HCFC-244eb和HCFC-225的原料组合物与相转移催化剂存在的碱性水溶液接触，从HCFC-225ca产生CFO-1214ya，同时从HCFC-244eb产生HFO-1234yf。
• MANUFACTURING METHOD OF 1-CHLORO-2,3,3,3-TETRAFLUOROPROPENE
  申请人：ASAHI GLASS COMPANY, LIMITED

  公开号：US20180297918A1

  公开（公告）日：2018-10-18

  There is provided an economically advantageous manufacturing method capable of efficiently obtaining 1-chloro-2,3,3,3-tetrafluoropropene by using 1,2-dichloro-2,3,3,3-tetrafluoropropane as a raw material. A manufacturing method of 1-chloro-2,3,3,3-tetrafluoropropene is characterized in that it includes subjecting 1,2-dichloro-2,3,3,3-tetrafluoropropane to a dehydrochlorination reaction in a liquid phase in a presence of a base.

  提供了一种经济优势的制造方法，能够有效地利用1,2-二氯-2,3,3,3-四氟丙烷作为原料，高效地获得1-氯-2,3,3,3-四氟丙烯。1-氯-2,3,3,3-四氟丙烯的制造方法的特点在于，它包括在碱的存在下将1,2-二氯-2,3,3,3-四氟丙烷在液相中进行脱氯化反应。
• [EN] CONTROLLED-RELEASE TYROSINE KINASE INHIBITOR COMPOUNDS WITH LOCALIZED PK PROPERTIES<br/>[FR] COMPOSÉS INHIBITEURS DE TYROSINE KINASE À LIBÉRATION CONTRÔLÉE PRÉSENTANT DES PROPRIÉTÉS PHARMACOCINÉTIQUES LOCALISÉES
  申请人：ASCENDIS PHARMA ONCOLOGY DIV A/S

  公开号：WO2020254613A1

  公开（公告）日：2020-12-24

  The present invention relates to a water-insoluble controlled-release tyrosine kinase inhibitor ("TKI") compound for use in the treatment of a cell-proliferation disorder, wherein said water-insoluble controlled-release TKI compound releases one or more TKI drug, wherein the water-insoluble controlled-release TKI compound is administered by intra-tissue administration and wherein the total amount of TKI moieties and TKI drug molecules remaining locally in such tissue 3 days after said intra-tissue administration is at least 25% of the amount of TKI moieties or TKI drug molecules administered by said intra-tissue administration; and to related aspects.

  本发明涉及一种水不溶性控释酪氨酸激酶抑制剂（“TKI”）化合物，用于治疗细胞增殖紊乱，其中所述水不溶性控释TKI化合物释放一种或多种TKI药物，所述水不溶性控释TKI化合物通过组织内给药给予，并且在所述组织内给药后的第3天，所述组织中残留的TKI基团和TKI药物分子的总量至少为所述组织内给药给予的TKI基团或TKI药物分子总量的25％；以及相关方面。
• [EN] MINIMIZATION OF SYSTEMIC INFLAMMATION<br/>[FR] MINIMISATION DE L'INFLAMMATION SYSTÉMIQUE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020141225A1

  公开（公告）日：2020-07-09

  The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist ("PRRA") for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA is administered by intra-tissue administration, and wherein the protein levels of at least one cytokine selected from the group consisting of IL-6, CCL2 and IL-10 in plasma has a more than 10-fold lower maximum protein level within 24 hours compared to an equivalent molar dose of the corresponding free PRRA upon intra/tissue administration; and to related aspects.

  本发明涉及一种用于治疗细胞增殖障碍的水不溶性控制释放模式识别受体激动剂（"PRRA"），其中水不溶性控制释放PRRA通过组织内给药进行，并且其中血浆中至少一种由IL-6、CCL2和IL-10组成的细胞因子的蛋白水平在24小时内与相应自由PRRA等摩尔剂量给药相比，最大蛋白水平降低超过10倍；以及相关方面。
• Extracts of Isochrysis sp.
  申请人：Herrmann Martina

  公开号：US20100080761A1

  公开（公告）日：2010-04-01

  The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.

  本发明涉及Isochrysissp.的提取物，优选为塔希提Isochrysis，及其在化妆品、皮肤病学和/或治疗学上的用途以及包含该Isochrysissp.提取物的化妆品、皮肤病学或治疗学产品，优选为塔希提Isochrysis。